Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Cecile Planquette"'
Publikováno v:
Blood. 132:5234-5234
Decitabine (DAC) is a hypomethylating agent indicated as front-line therapy for de novo or secondary acute myeloid leukemia (AML) in newly diagnosed patients aged 65 years or older unfit for standard induction chemotherapy (Kantarjian et al., 2012, M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8f9ebbbd92dba83c662bdfc3267460a
https://doi.org/10.1182/blood-2018-99-118125
https://doi.org/10.1182/blood-2018-99-118125
Publikováno v:
Blood. 132:1447-1447
Daratumumab (DARA), the first monoclonal antibody directed against CD38, received accelerated approval in 2015 and regular approval in 2016 by the Food and Drug Administration for the treatment of relapsed/refractory multiple myeloma (MM) (Bhatnagar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5db13579d325755310bd5f5bb916984
https://doi.org/10.1182/blood-2018-99-110527
https://doi.org/10.1182/blood-2018-99-110527
Publikováno v:
Cancer Research. 78:1890-1890
Acute myeloid leukemia (AML) is a heterogeneous disease classified into 9 FAB subtypes according to the origin and/or maturity of the malignant cells: M0 undifferentiated, M1 minimally mature myeloblastic, M2 mature myeloblastic, M3 promyelocytic, M4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59a748244d4cad8882c27d9b61452e9f
https://doi.org/10.1158/1538-7445.am2018-1890
https://doi.org/10.1158/1538-7445.am2018-1890
Autor:
Wolfgang Sippl, Xavier Jacq, Philippe Guedat, Julie Bianchi, Alessandra Calabrese, Remi Delansorne, Guillaume Boissy, Frédéric Colland, Cecile Planquette, Virginie Trouplin, Laurent Daviet, Jacques Camonis, Vincent Collura, Céline Reverdy, Catherine Borg-Capra, Jean-Christophe Rain, Susan Conrath, Vasily N. Aushev, Etienne Formstecher
Publikováno v:
Molecular Cancer Therapeutics. 8:2286-2295
Deregulation of the ubiquitin/proteasome system has been implicated in the pathogenesis of many human diseases, including cancer. Ubiquitin-specific proteases (USP) are cysteine proteases involved in the deubiquitination of protein substrates. Functi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::260d0f5f1750235b0d3467ab67d07cb0
https://doi.org/10.1158/1535-7163.mct-09-0097
https://doi.org/10.1158/1535-7163.mct-09-0097
Publikováno v:
Cancer Research. 77:2124-2124
Inecalcitol is a vitamin D receptor (VDR) agonist characterized by a high antiproliferative activity on various cancer cell lines (Okamoto et al., 2012; Ma et al., 2013) and a low calcemic potential as demonstrated by the high maximal tolerated oral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0bae038c7e57b16d3662f2103fd9d25
https://doi.org/10.1158/1538-7445.am2017-2124
https://doi.org/10.1158/1538-7445.am2017-2124
Publikováno v:
Blood. 128:3521-3521
Targeting CD38 has proven to be an effective strategy for the treatment of relapsed refractory multiple myeloma (MM), with the recent approval of the first therapeutic monoclonal antibody directed against human CD38: daratumumab (Sanchez L et al., 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f7e171ad2775bcdeaef0e8f232e939b
https://doi.org/10.1182/blood.v128.22.3521.3521
https://doi.org/10.1182/blood.v128.22.3521.3521
Autor:
Mickael Cholay, Etienne Formstecher, Heike Lehrmann, Frédéric Colland, Cecile Planquette, Khalil Arar, Virginie Trouplin, Alessandra Calabrese, Sandra Aresta, Laurent Daviet, Céline Reverdy
Publikováno v:
Oligonucleotides. 16(4)
Gene silencing by RNA interference (RNAi) has proven to be a powerful tool for investigating gene function in mammalian cells. Combination of several short interfering RNA (siRNA) targeting the same gene is commonly used to improve RNA interference.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2a03fd6676c9f42f8e3e78f6b2a115
https://pubmed.ncbi.nlm.nih.gov/17155913
https://pubmed.ncbi.nlm.nih.gov/17155913
Autor:
Susan Conrath, Roman Lopez, Philippe Guedat, Vincent Collura, Frédéric Colland, Cecile Planquette, Céline Reverdy, Remi Delansorne, Laurent Daviet
Publikováno v:
Cancer Research. 70:2642-2642
Regulated protein turnover is primarily controlled by the ubiquitin-proteasome system. The only marketed drug related to the ubiquitin-proteasome system, bortezomib, is acting as a proteasome inhibitor and has been approved for the treatment of some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3bc2fee96686445df8c6ef40cc8ac272
https://doi.org/10.1158/1538-7445.am10-2642
https://doi.org/10.1158/1538-7445.am10-2642
Autor:
Vincent Collura, Céline Reverdy, Frédéric Colland, Remi Delansorne, Cecile Planquette, Susan Conrath, Roman Lopez, Laurent Daviet, Philippe Guedat
Publikováno v:
Molecular Cancer Therapeutics. 8:B193-B193
Regulated protein turnover is primarily controlled by the ubiquitin-proteasome system. The therapeutic efficacy of the proteasome inhibitor Bortezomib establishes this system as a valid anticancer therapeutic field. A promising alternative to targeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6f3e599316612f863e74b4cefcad7af
https://doi.org/10.1158/1535-7163.targ-09-b193
https://doi.org/10.1158/1535-7163.targ-09-b193
Autor:
Etienne Formstecher, Celine Reverdy, Mickael Cholay, Cecile Planquette, Virginie Trouplin, Heike Lehrmann, Sandra Aresta, Alessandra Calabrese, Khalil Arar, Laurent Daviet, Frederic Colland
Publikováno v:
Oligonucleotides; Vol. 16 Issue 4, p387-394, 8p